RS60365B1 - Lečenje alopecije areate - Google Patents

Lečenje alopecije areate

Info

Publication number
RS60365B1
RS60365B1 RS20200322A RSP20200322A RS60365B1 RS 60365 B1 RS60365 B1 RS 60365B1 RS 20200322 A RS20200322 A RS 20200322A RS P20200322 A RSP20200322 A RS P20200322A RS 60365 B1 RS60365 B1 RS 60365B1
Authority
RS
Serbia
Prior art keywords
compound
treatment
clause
oxopropanenitrile
pyrrolo
Prior art date
Application number
RS20200322A
Other languages
English (en)
Serbian (sr)
Inventor
Michael Sierra
Tord Labuda
Atsuo Tanimoto
Yuichi Shinozaki
Original Assignee
Leo Pharma As
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015190849A external-priority patent/JP2017066061A/ja
Application filed by Leo Pharma As, Japan Tobacco Inc filed Critical Leo Pharma As
Publication of RS60365B1 publication Critical patent/RS60365B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RS20200322A 2015-09-24 2016-09-22 Lečenje alopecije areate RS60365B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15186644 2015-09-24
JP2015190849A JP2017066061A (ja) 2015-09-29 2015-09-29 円形脱毛症治療剤
PCT/EP2016/072531 WO2017050891A1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata
EP16775134.6A EP3352734B1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata

Publications (1)

Publication Number Publication Date
RS60365B1 true RS60365B1 (sr) 2020-07-31

Family

ID=57047187

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200322A RS60365B1 (sr) 2015-09-24 2016-09-22 Lečenje alopecije areate

Country Status (27)

Country Link
US (3) US20180263986A1 (enExample)
EP (1) EP3352734B1 (enExample)
JP (1) JP6776345B2 (enExample)
KR (1) KR102728341B1 (enExample)
CN (1) CN108135834B (enExample)
AU (3) AU2016325388A1 (enExample)
BR (1) BR112018005771B1 (enExample)
CA (1) CA2998972A1 (enExample)
CY (1) CY1122837T1 (enExample)
DK (1) DK3352734T3 (enExample)
ES (1) ES2779762T3 (enExample)
HR (1) HRP20200472T1 (enExample)
HU (1) HUE049052T2 (enExample)
IL (3) IL312861A (enExample)
LT (1) LT3352734T (enExample)
MX (1) MX375024B (enExample)
MY (1) MY196541A (enExample)
PL (1) PL3352734T3 (enExample)
PT (1) PT3352734T (enExample)
RS (1) RS60365B1 (enExample)
RU (1) RU2754997C2 (enExample)
SG (1) SG10202111361TA (enExample)
SI (1) SI3352734T1 (enExample)
TW (1) TWI720022B (enExample)
UA (1) UA124192C2 (enExample)
WO (1) WO2017050891A1 (enExample)
ZA (1) ZA201801722B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤

Also Published As

Publication number Publication date
JP2018528238A (ja) 2018-09-27
SG10202111361TA (en) 2021-12-30
UA124192C2 (uk) 2021-08-04
LT3352734T (lt) 2020-04-10
DK3352734T3 (da) 2020-03-30
ZA201801722B (en) 2025-06-25
AU2016325388A1 (en) 2018-03-29
EP3352734B1 (en) 2020-01-15
NZ740690A (en) 2024-11-29
ES2779762T3 (es) 2020-08-19
RU2754997C2 (ru) 2021-09-08
EP3352734A1 (en) 2018-08-01
IL298520A (en) 2023-01-01
SI3352734T1 (sl) 2020-07-31
BR112018005771B1 (pt) 2023-12-05
HUE049052T2 (hu) 2020-09-28
MY196541A (en) 2023-04-19
CA2998972A1 (en) 2017-03-30
CN108135834A (zh) 2018-06-08
US20180263986A1 (en) 2018-09-20
KR20180054767A (ko) 2018-05-24
IL312861A (en) 2024-07-01
AU2024204716B2 (en) 2026-06-11
AU2022202508A1 (en) 2022-05-12
HRP20200472T1 (hr) 2020-09-18
JP6776345B2 (ja) 2020-10-28
US20240398809A1 (en) 2024-12-05
RU2018114922A (ru) 2019-10-28
MX2018003332A (es) 2018-08-16
PL3352734T3 (pl) 2020-08-24
TWI720022B (zh) 2021-03-01
CN108135834B (zh) 2021-07-27
WO2017050891A1 (en) 2017-03-30
PT3352734T (pt) 2020-03-31
RU2018114922A3 (enExample) 2019-12-11
US20220088020A1 (en) 2022-03-24
BR112018005771A2 (pt) 2018-10-09
AU2024204716A1 (en) 2024-07-25
KR102728341B1 (ko) 2024-11-11
MX375024B (es) 2025-03-06
HK1257770A1 (en) 2019-10-25
TW201717955A (zh) 2017-06-01
IL257918A (en) 2018-05-31
CY1122837T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
US20240398809A1 (en) Treatment of alopecia areata
US20230355628A1 (en) Topical treatment of vitiligo by a jak inhibitor
CN114786660A (zh) 使用mtorc1调节剂的治疗方法
US20240366582A1 (en) Treatment of raynaud's disease
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US20250275974A1 (en) Treatment of frontal fibrosing alopecia
JP2017149767A (ja) 7−(1h−イミダゾール−4−イルメチル)−5,6,7,8−テトラヒドロキノリンを含む肌の疾患および状態を治療するための医薬組成物
WO2001000196A2 (en) Mirtazapine for weight gain in wasting diseases
HK1257770B (en) Treatment of alopecia areata
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
WO2025085050A1 (en) Treatment of frontal fibrosing alopecia